Less than two months ago, Roche (ROG: SIX) and Alnylam Pharmaceuticals (Nasdaq: ALNY) announced a partnership to co-develop and co-commercialize zilebesiran.
Potentially worth more than $3 billion to Alnylam, the partnership is already appearing promising.
"These early results indicate the potential for zilebesiran to achieve sustained blood pressure reduction with quarterly or biannual dosing"On Friday, the companies announced that the Phase II study of the investigational RNAi therapeutic targeting liver-expressed angiotensinogen (AGT) had met its primary endpoint.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze